tbuckley/cabot-search huggingface dataset:
HSR20-088: Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer
Authors: Ani John, Baiyu Yang, Jaya Madala, Roma Shah
Journal: Journal of the National Comprehensive Cancer Network (2020)

"HSR20-088: Clinical Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer" published on 20 Mar 2020 by National Comprehensive Cancer Network.
APPLYING THE SIMPLIFIED RENAL INDEX SCORING SCHEME (SRISS) FOR ESTIMATING RISK OF POSTOPERATIVE RENAL REPLACEMENT THERAPY IN BRAZILIAN CARDIAC SURGERY POPULATION
Authors: Marcelo Arruda Nakazone, Maurício N. Machado, Cristiane C. Singulane, Fernando B. Rodrigues, Lilia N. Maia
Journal: Journal of the American College of Cardiology (2020)
Erratum: Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Authors: Sandeep T Patil, Lu Zhang, Ferenc Martenyi, Stephen L Lowe, Kimberley A Jackson, Boris V Andreev, Alla S Avedisova, Leonid M Bardenstein, Issak Y Gurovich, Margarita A Morozova, Sergey N Mosolov, Nikolai G Neznanov, Alexander M Reznik, Anatoly B Smulevich, Vladimir A Tochilov, Bryan G Johnson, James A Monn, Darryle D Schoepp
Journal: Nature Medicine (2007)
A serine protease inhibitor suppresses autoimmune neuroinflammation by activating the STING/IFN-β axis in macrophages
Authors: Giacomo Casella, Javad Rasouli, Keyonna Mason, Alexandra Boehm, Gaurav Kumar, Daniel Hwang, Rodolfo Thome, Larissa Ishikawa, Guang-Xian Zhang, Bogoljub Ciric, Abdolmohamad Rostami
Journal: Cellular and Molecular Immunology (2020)
Cumulative Exposure to Infliximab, But Not Trough Concentrations, Correlates With Rate of Infection
Authors: Amandine Landemaine, Antoine Petitcollin, Charlène Brochard, Céline Miard, Marie Dewitte, Eric Le Balc’h, Thomas Grainville, Eric Bellissant, Laurent Siproudhis, Guillaume Bouguen
Journal: Clinical Gastroenterology and Hepatology (2020)
Therapy prediction in a breast cancer primary systemic chemotherapy (PST) study applying docetaxel/epirubicin/cyclophosphamide (TEC) by gene expression profiling
Authors: U. Vogt, B. Brandt, U. Bosse, U. Bonk, H. Adigüzel, Y. Ergoenenc, D. Kemming, C. Schlotter
Journal: Journal of Clinical Oncology (2006)

10049 Background: Currently there are no tests to assist in selecting the optimal PST regimen for breast cancer patients. Primary study goals of this prospective, single-armed multicentric investigation are pathologically confirmed tumor response and the rate of breast conserving therapy (BCT). Secondary goals are to find histopathologic and gene profiling patterns best correlating with tumor remission in a taxane- anthracycline based neoadjuvant setting as well as to evaluate cytostatic toxicity and quality of life. Methods: In this phase II study of totally 40 eligible patients with invasive breast cancer Human Genome Survey Microarray (HGSM) expression profiling is performed on jet-biopsy sample basis. The protocol was elaborated for the treatment of patients suffering from a primary tumor with 6 cycles of TEC (3-weekly) prior to the surgical treatment. The selection of predictor genes was done with BRB-ArrayTools Version 3.3 using a model based on the Compound Covariate Predictor, Diagonal Linear Discriminant Analysis, Nearest Neighbor Classification, and Support Vector Machines with linear kernel.We estimated the prediction error of each model using leave-one-out cross-validation (LOOCV) as described by Simon R. 2000 random permutations were used. Clustering was done using Cluster 3.0 and Java TreeView 1.0.12. Results: Tumor response (pCR, pPR) of more than 70% can be achieved using neoadjuvant TEC-regimen. 22% pCR (ypT0; ypN0) and 90% BCT in this study are comparable with data of other published PST trials. Preliminary expression profiling results reveal a subset of 148 genes that classifies all patients with a complete remission (pCR), in one cluster with a very closely related gene expression pattern (n=5; PPV = 100%). Furthermore 10 patients defined as responders due to selected MIB1-expression based criteria (expressing cells in the residual tumor ≤ 5% and a Δ MIB1-expression ≥ 20%) can be correctly classified in 9 of 10 cases. Comparable separation of the groups could not be achieved by established tumor factors. Conclusions: HGSM expression profiling is promising to have the potential to figure out genes that are related to chemotherapy response, especially in PST. No significant financial relationships to disclose.
An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia
Authors: Tun Kiat Ko, Asif Javed, Kian Leong Lee, Thushangi N. Pathiraja, Xingliang Liu, Simeen Malik, Sheila Xinxuan Soh, Xiu Ting Heng, Naoto Takahashi, Joanna H. J. Tan, Ravi Bhatia, Alexis J. Khng, Wee-Joo Chng, Yee Yen Sia, David A. Fruman, King Pan Ng, Zhu En Chan, Kim Jiajing Xie, Qiangze Hoi, Cheryl Xueli Chan, Audrey S. M. Teo, Oscar Velazquez Camacho, Wee Yang Meah, Chiea Chuen Khor, Chin Thing J. Ong, Wei Jia W. Soon, Patrick Tan, Pauline C. Ng, Charles Chuah, Axel M. Hillmer, S. Tiong Ong
Journal: Blood (2020)
CHANGES IN HIGH-SENSITIVITY TROPONIN AND THE RISK OF INCIDENT CARDIOVASCULAR EVENTS: THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS (MESA)
Authors: Frank Qian, Norrina Allen, Megan McCabe, Christopher R. DeFilippi, Joseph A. Delaney, Vijay Nambi, Stephen Seliger, Philip Greenland, Tamar Polonsky
Journal: Journal of the American College of Cardiology (2020)
Assessment of executive function (EF) among pediatric survivors of acute lymphoblastic leukemia (ALL).
Authors: Lyn M Balsamo, Kyaw J Sint, Joseph Philip Neglia, Nina Kadan-Lottick
Journal: Journal of Clinical Oncology (2013)

9584 Background: Childhood ALL survivors are at increased risk of impaired EF. Both parent ratings and performance-based measures are used to identify vulnerable patients. We seek to assess the association between these modalities to 1) each other, and 2) need for special education and stimulants. Methods: This 22-site cross-sectional study included 256 children in remission for standard-risk precursor-B ALL previously enrolled on legacy Children's Oncology Protocols from 1993 - 2000. Patients had no history of CNS leukemia, cranial radiation, or pre-existing neurodevelopmental disorders; were ≥1 year off-therapy; and were 6-16 years at evaluation. Patients were administered performance-based measures of working memory, Digit Span (DS) and Letter-Number Sequencing (LNS) comprising the Working Memory Index (WMI) from the Wechsler Intelligence Scales for Children - Fourth Edition. Patients completed the Controlled Oral Word Association Test (COWAT). Parents completed demographic surveys and a Likert-scale assessment of executive processes, Behavior Rating Inventory of Executive Function (BRIEF). Results: There were modest correlations between BRIEF-WM scale and WMI (r=-0.20, p&lt;0.01) and subscales, DS (r=-0.17, p&lt;0.01) and LNS (r=-0.19, p&lt;0.01). BRIEF-Initiate and COWAT (r=-0.22, p&lt;0.01) were correlated. However, impaired classification based on performance-based measures was a poor predictor of parent assessment classification. The WMI and BRIEF-WM independently predicted receipt of special education (p=0.0017 and 0.0003). The BRIEF-WM and Initiate scales predicted stimulant medication use (p&lt;0.0001 and p=0.0037); however, performance-based measures did not. Conclusions: Rater and performance-based measures provide related, but different information about EF indicating the need for both. Both measurement modalities capture educational difficulties; however, only parent ratings are associated with stimulants. This may reflect the medication's success in modifying cognition in controlled environments and the BRIEF's sensitivity to the child's ability to execute tasks in the real-world setting.
Low Spontaneous Mutation Rate and Pleistocene Radiation of Pea Aphids
Authors: Varvara Fazalova, Bruno Nevado
Journal: Molecular Biology and Evolution (2020)

Abstract Accurate estimates of divergence times are essential to understand the evolutionary history of species. It allows linking evolutionary histories of the diverging lineages with past geological, climatic, and other changes in environment and shed light on the processes involved in speciation. The pea aphid radiation includes multiple host races adapted to different legume host plants. It is thought that diversification in this system occurred very recently, over the past 8,000–16,000 years. This young age estimate was used to link diversification in pea aphids to the onset of human agriculture, and led to the establishment of the pea aphid radiation as a model system in the study of speciation with gene flow. Here, we re-examine the age of the pea aphid radiation, by combining a mutation accumulation experiment with a genome-wide estimate of divergence between distantly related pea aphid host races. We estimate the spontaneous mutation rate for pea aphids as 2.7×10-10 per haploid genome per parthenogenic generation. Using this estimate of mutation rate and the genome-wide genetic differentiation observed between pea aphid host races, we show that the pea aphid radiation is much more ancient than assumed previously, predating Neolithic agriculture by several hundreds of thousands of years. Our results rule out human agriculture as the driver of diversification of the pea aphid radiation, and call for re-assessment of the role of allopatric isolation during Pleistocene climatic oscillations in divergence of the pea aphid complex.
Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram
Authors: Andrea Maurichi, Rosalba Miceli, Hanna Eriksson, Julia Newton-Bishop, Jérémie Nsengimana, May Chan, Andrew J. Hayes, Kara Heelan, David Adams, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Catherine Harwood, Daniele Bergamaschi, Dorothy Bennett, Konstantinos Lasithiotakis, Paola Ghiorzo, Bruna Dalmasso, Ausilia Manganoni, Francesca Consoli, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Vittoria Espeli, Cristina Mangas, Pietro Quaglino, Simone Ribero, Paolo Broganelli, Giovanni Pellacani, Caterina Longo, Corrado Del Forno, Lorenzo Borgognoni, Serena Sestini, Nicola Pimpinelli, Sara Fortunato, Alessandra Chiarugi, Paolo Nardini, Elena Morittu, Antonio Florita, Mara Cossa, Barbara Valeri, Massimo Milione, Giancarlo Pruneri, Odysseas Zoras, Andrea Anichini, Roberta Mortarini, Mario Santinami
Journal: Journal of Clinical Oncology (2020)

Thin melanomas (T1; ≤ 1 mm) constitute 70% of newly diagnosed cutaneous melanomas. Regional node metastasis determined by sentinel node biopsy (SNB) is an important prognostic factor for T1 melanoma. However, current melanoma guidelines do not provide clear indications on when to perform SNB in T1 disease and stress an individualized approach to SNB that considers all clinicopathologic risk factors. We aimed to identify determinants of sentinel node (SN) status for incorporation into an externally validated nomogram to better select patients with T1 disease for SNB.
REAL-TIME IN-VITRO MALFUNCTIONS IN WIRELESS-ENABLED PACEMAKERS AND ICDS DURING ONCOLOGIC RADIOTHERAPY
Authors: Enrico Di Girolamo, Massimiliano Marini, Paolo De Filippo, Marianna Appignani, Massimiliano Faustino, Fabrizio Di Girolamo, Cristina Leidi, Anna Delana, Agnese Barbareschi, Stefano Andreoli, Domenico Genovesi, Maria Daniela Falco
Journal: Journal of the American College of Cardiology (2020)
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
Authors: Maud Mayoux, Andreas Roller, Vesna Pulko, Stefano Sammicheli, Stanford Chen, Eva Sum, Christian Jost, Marieke F. Fransen, Regula B. Buser, Marcin Kowanetz, Karolin Rommel, Ines Matos, Sara Colombetti, Anton Belousov, Vaios Karanikas, Ferry Ossendorp, Priti S. Hegde, Daniel S. Chen, Pablo Umana, Mario Perro, Christian Klein, Wei Xu
Journal: Science Translational Medicine (2020)

PD-L1/PD-1 blocking antibodies have demonstrated therapeutic efficacy across a range of human cancers. Extending this benefit to a greater number of patients, however, will require a better understanding of how these therapies instigate anticancer immunity. Although the PD-L1/PD-1 axis is typically associated with T cell function, we demonstrate here that dendritic cells (DCs) are an important target of PD-L1 blocking antibody. PD-L1 binds two receptors, PD-1 and B7.1 (CD80). PD-L1 is expressed much more abundantly than B7.1 on peripheral and tumor-associated DCs in patients with cancer. Blocking PD-L1 on DCs relieves B7.1 sequestration in cis by PD-L1, which allows the B7.1/CD28 interaction to enhance T cell priming. In line with this, in patients with renal cell carcinoma or non-small cell lung cancer treated with atezolizumab (PD-L1 blockade), a DC gene signature is strongly associated with improved overall survival. These data suggest that PD-L1 blockade reinvigorates DC function to generate potent anticancer T cell immunity.
Depression and self-reported memory problems in adult-onset cancer survivors.
Authors: Pascal Jean-Pierre, Paul Winters
Journal: Journal of Clinical Oncology (2013)

9586 Background: Memory impairments are debilitating adverse effects of cancer and its treatments. Depression may predispose or exacerbate memory problems. We examined the relationship between depression and memory problems in adult-onset cancer survivors. Methods: We included data from individuals who completed the National Health and Nutrition Examination Survey, a nationally representative, stratified, multistage probability sample of the civilian, non-institutionalized population of the United States from 2005 to 2010. We excluded individuals with a history of brain cancer or stroke since these conditions are expected to cause cognitive problems because of direct brain insults. We determined the prevalence of depression and its relationship to memory problems in cancer survivors by weighting our results proportionally. We controlled for demographic predictors of memory problems. Results: The sample included 14249 adults (6875 men and 7274 women) age 20 years and older. There were 6959 Whites, 2792 Blacks, 3903 Hispanics, and 589 other race/multiracial. Overall, individuals in the United States with a history of depression were 8.4 times more likely to report memory problems (Odds Ratio (OR), 8.406; 95%CI, 6.73 to 10.64). We further explored the depression-memory relationship in a subsample of cancer survivors. Adjusting for age, sex, race-ethnicity, education, income, and general health, cancer survivors with a history of depression were approximately 5 times more likely to report memory problems (N=1283; OR, 4.921; 95%CI, 2.141 to 11.313) than those without a history of depression. Other predictors of memory problems were age (≥ 60 years old, OR = 4.756, 95%CI, 1.957 to 11.560) and lower income (OR, 3.721; 95%CI, 1.951 to 7.098). Conclusions: The likelihood of memory problems is higher in cancer survivors with a history of depression. Future studies are needed to systematically delineate the depression-memory problems relationship, and to inform the development of interventions to treat these conditions for cancer survivors.
DO EARLY CHANGES IN LEFT VENTRICULAR EJECTION FRACTION PREDICT LONG-TERM OUTCOMES AFTER TRANSCATHETER MITRAL VALVE REPAIR OF SECONDARY MITRAL REGURGITATION? THE COAPT TRIAL
Authors: Stamatios Lerakis, Annapoorna Subhash Kini, Federico M. Asch, Neil J. Weissman, Paul A. Grayburn, Saibal Kar, None Kar, Scott Lim, Jacob M. Mishell, Brian Whisenant, Michael Rinaldi, Samir R. Kapadia, Vivek Rajagopal, Ian Joseph Sarembock, Andreas Brieke, Gilbert Tang, Aaron Crowley, Samin K. Sharma, JoAnn Lindenfeld, William Abraham, Michael Mack, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2020)
Change in circulating endothelial cells (CEC) predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevacizumab (B)
Authors: H. S. Rugo, M. N. Dickler, T. A. Traina, J. H. Scott, D. H. Moore, J. Bruckner, C. Hudis, J. W. Park
Journal: Journal of Clinical Oncology (2006)

3039 Background: Antiangiogenic therapy has demonstrated efficacy in the treatment (tx) of metastatic breast cancer. Mechanism-based biomarkers of antiangiogenic therapy, if clinically validated, offer the potential to optimize this novel therapy. CECs have been proposed as a marker of tumor progression and/or response to antiangiogenic therapy with B. We performed a feasibility study testing B combined with L for the tx of hormone receptor-positive MBC. To explore markers of activity and response, we assayed CECs and circulating tumor cells (CTCs) at weeks (wks) 0 (baseline), 3, 12, and then Q 12 wks. Methods: CECs were defined as CD34/31+, CD45-. Progenitor (CD133+) (CECp) and activation markers (CD106+) were also measured. For CECs, 50 ul of blood was stained with the indicated MAbs; after RBC lysis, flow cytometry (FC) was performed for total CEC and CECp. For CTCs, 20 ml of blood was subjected to immunomagnetic capture using anti-EpCAM ferrofluid, followed by FC for EpCAM, CD45, and nucleic acid content. The log rank test was used to test for significant differences related to response. Results: 32 of 42 pts have been enrolled. As separately reported, prior non-steroidal AI (NSAI) use without progression is permitted; median (med) time on L before start of B was 6 mo (1–52). 28 pts have at least baseline and week 3 CEC and CTC along with clinical response data. Med CEC level at baseline was 10.4 CEC/ul (4–38); the peak value at any time point was 107. CTC levels were much less frequent with a med of 0.3 CTC/ml (0–95, and highest value 1153). An increase in CECs at wk 3 compared to wk 0 predicted worse PFS (p = 0.015). CTCs were ≤ 0.1 at study start in 40% of pts and ≥ 1.0 in only 17%, likely due to length of prior L; change in values at wk 3 did not correlate with PFS in this pretreated group. Conclusions: Consistent with our previous results in a separate trial of B containing treatment in MBC, changes in CEC levels appear to be a biomarker of response/progression on antiangiogenic therapy. CTCs did not reflect response or progression in this population of patients, likely due to lengthy prior exposure to letrozole. Supported in part by Genentech and Novartis. [Table: see text]
The effectiveness of interventions to improve self‐management for adolescents and young adults with allergic conditions: A systematic review
Authors: Rebecca C. Knibb, Cherry Alviani, Teresa Garriga‐Baraut, Charlotte G. Mortz, Marta Vazquez‐Ortiz, Elizabeth Angier, Katerina Blumchen, Pasquale Comberiati, Bettina Duca, Audrey DunnGalvin, Claudia Gore, Valerie Hox, Britt Jensen, Helena Pite, Alexandra F. Santos, Silvia Sanchez‐Garcia, M. Hazel Gowland, Frans Timmermans, Graham Roberts
Journal: Allergy (2020)

Abstract Background This systematic review aimed to review the literature on interventions for improving self‐management and well‐being in adolescents and young adults (11‐25 years) with asthma and allergic conditions. Methods A systematic literature search was undertaken across eight databases. References were checked by two reviewers for inclusion. Study data were extracted, and their quality was assessed in duplicate. A narrative synthesis was undertaken. Results A total of 30 papers reporting data from 27 studies were included. Interventions types were psychological ( k = 9); e‐health ( k = 8); educational ( k = 4); peer‐led ( k = 5); breathing re‐training ( k = 1). All interventions were for asthma. Psychological interventions resulted in significant improvements in the intervention group compared with the control group for self‐esteem, quality of life, self‐efficacy, coping strategies, mood and asthma symptoms. E‐Health interventions reported significant improvements for inhaler technique, adherence and quality of life. General educational interventions demonstrated significantly improved quality of life, management of asthma symptoms, controller medication use, increased use of a written management plan and reduction in symptoms. The peer‐led interventions included the Triple A (Adolescent Asthma Action) programme and a peer‐led camp based on the Power Breathing Programme. Improvements were found for self‐efficacy, school absenteeism and quality of life. Conclusion Although significant improvements were seen for all intervention types, many were small feasibility or pilot studies, few studies reported effect sizes and no studies for allergic conditions other than asthma met the inclusion criteria. Research using large longitudinal interventional designs across the range of allergic conditions is required to strengthen the evidence base.
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) using highly specific antibody against recombinant human DPD (rhDPD) in gastric scirrhous cancer treated with S-1, new DPD inhibitory fluoropyrimidine
Authors: T. Shimizu, Y. Yamada, K. Shirao, H. Yasui, H. Morita, K. Tamura, T. Ozaki, M. Fukuoka
Journal: Journal of Clinical Oncology (2006)

14053 Background: Highly specific antibody against recombinant human dihydropyrimidine dehydrogenase (DPD) has been developed to assess immunohistochemically DPD expression in tumors. A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous cancer. Objective of this study was to assess intra-tumoral levels of DPD immunohistochemically using highly specific anti-DPD polyclonal antibodies, and investigated the relationship between the immunoreactivity of DPD and the anti-tumor effects of S-1 as a DIF in gastric scirrhous cancer patients. Methods: The relationship between immunoreactivity to DPD in biopsy specimens and the effects of chemotherapy was investigated in 61 patients treated with first-line fluoropyrimidine-based chemotherapy (S-1:DIF, 5-FU:non-DIF) for gastric scirrhous cancer. Immunohistochemical staining intensity was semiquantitatively graded (− to 3+) on the basis of the proportion of positively stained cancer cells in the lesions. Results: Total 61 gastric scirrhous cancer patients (M/F: 34/27) were analyzed to date with a median age of 56 (range 30–73). Response rate (partial response) was significantly higher in patients with DPD positive tumors than in those with negative in S-1 group (45.5%, 10.0% : p&lt;0.05), as compared with in 5-FU group (0%, 5.6%: p=0.398). According to median survival time, there was no significant difference between patients with DPD positive tumors (364 days) and those with negative (406 days; p=0.626) in S-1 group or in 5-FU group (181 days and 256 days, respectively; p=0.543). Conclusions: This study indicates that S-1 is effective even in gastric scirrhous cancer with the high level of DPD activity. Further immunohistochemical studies using DIF-based regimens are needed to confirm these results with larger numbers of patients. No significant financial relationships to disclose.
SCAI CARDIOGENIC SHOCK CLASSIFICATION SYSTEM TO PREDICT SURVIVAL
Authors: Tara Jones, Iosif Taleb, Elizabeth Dranow, Jason Chaney, Stephen McKellar, Antigone G. Koliopoulou, Craig Selzman, James Fang, Jose Nativi-Nicolau, Joseph Tonna, Sean Overton, Josef Stehlik, Frederick Welt, Anwar Tandar, Stavros Drakos
Journal: Journal of the American College of Cardiology (2020)